Hepatitis B and C Seroprevalence in Solid Tumors - Necessity for Screening During Chemotherapy

• DOI: 10.7314/apjcp.2014.15.3.1411
• Publication Date: 2014-07-10T07:43:03Z
• Authors: Arzu Oguz; Fatma Aykas; Dilek Unal; Samet Karahan; Emine Uslu; Mustafa Basak; Ahmet Karaman
• Keywords: Seroprevalence; Hepatitis B

Hepatitis B and C are the leading causes of liver diseases worldwide. For hematological solid malignancy patients undergoing chemotherapy, increases in HBV DNA HCV RNA levels can be detected which may result reactivation hepatitis-related morbidity mortality. The aim this study was to determine seroprevalence Hbs ag Anti positivity with malignancies chemotherapy consequences during follow-up.The files 914 whose hepatitis markers were determined serologically at diagnosis reviewed retrospectively. All underwent adjuvant/palliative chemotherapy. cases and/or positivity, levels, function tests follow-up treatment modalities that chosen determined.Of cases, Ag, anti 40 (4.4%), 336 (36.8%) 26 (2.8%) respectively. positive received prophylactic lamuvidine before start In failure not a delay courses because encountered.Just as malignancies, screening for should also considered tumors Prophylactic antiviral therapy reduces both rates related mortality morbidity. clinical impact infection on is still well characterized.